Introduction
Recombinant viral vectors hold great promise in the field of cancer gene therapy. Much effort is devoted to generating vectors that have the ability to specifically transduce tumor cells. In this respect it will be of major interest to develop vectors that are targeted to antigens that are specifically expressed at the surface of tumor cells to prevent transduction of noncancerous cells.
Intriguingly, in many cases cancer cells have been found to induce a tumor cell-specific response of the immune system. Cytotoxic T lymphocytes (CTLs) have been discovered that eradicate tumor cells via the recognition of tumor-specific antigens, while leaving healthy tissue intact. Such tumor-specific antigens might belong to the group of so-called 'cancer-testis' (CT) antigens, which are presented at the tumor cell surface by major histocompatibility complex (MHC) class I molecules and are recognized by CTLs. 1 CT antigens are expressed in a variety of cancerous tissues and are generally silent in normal tissues, except for the testis. 2 To date, 89 CT genes or isoforms, which are organized into 44 families, have been described. From these, 19 families are testis restricted, 11 show additional expression in one or two somatic tissues, 9 are expressed in three to six tissue types besides testis and 5 are ubiquitously somatically expressed. With the exception of the testis-restricted CT antigens, the others also show expression in the pancreas but at levels as much as 10 times lower than in the testis. 2 Expression of CT antigens was first shown in melanoma and all the classic CT antigens are expressed in this type of tumor, but since the 1980s, expression in various other tumors has been recognized. 2 The highly specific expression profiles of the CT antigens make them interesting target molecules for cancer therapies. Importantly, CT antigens belonging to the melanoma-associated antigen (MAGE) A, B and C family seem to be involved in oncogenesis, providing protection against apoptosis in tumor cells. 3 The expression of other tumor antigens, such as 'overexpression' antigens p53 and HER-2/neu, or 'differentiation antigens' gp100 and Mart-1, is less restricted to tumor cells and their use for cancer-drug targeting may be associated with negative side effects.
The principle of targeting human MHC class I molecules (human leukocyte antigen, HLA class I), in complex with tumor-specific antigens, has been the subject of many studies on T-cell targeting to tumor cells. 4 So far, HLA class I/peptide targeting of viral vectors has not been extensively explored. Promising results have been obtained by targeting measles virus particles to a specific HLA class I/peptide complex via fusion of a single-chain T-cell receptor (scTCR) to the attachment protein H of the virus. 5 Recently, adenovirus has been also retargeted to CT antigens by replacing the knob domain of the fiber protein with a CT antigenspecific scTCR. 6 Adenoviral vectors are among the most promising viral vectors for cancer gene therapy for several reasons. They can be produced in large quantities, they do not lead to stable genetic modification of the transduced cells and they have a good safety profile. 7 Genetic modification of adenoviral capsid proteins might lead to the development of vectors that are specifically targeted to tumor cells, thereby improving safety and efficacy. Cell binding of subgroup C-derived human adenovirus (HAdV) vectors (including HAdV-5 and HAdV-2), which are widely used in gene therapy, involves two distinct steps. First, they bind with high affinity to the coxsackie virus and adenovirus receptor (CAR) at the cell surface. Second, interaction of penton base Arg-Gly-Asp (RGD) motifs with cellular integrins, including avb3 and avb5 leads to endocytosis. 8 Many tumor cells are relatively refractory to infection by subgroup C-derived HAdV vectors due to the paucity of CAR receptors. 9 Development of genetically modified vectors that can infect CARnegative cells has mainly focused on incorporation of heterologous ligands in the fiber knob, or on replacement of the entire knob domain by a heterologous ligand. 7 The complexity of incorporating ligands into the adenovirus fiber locale has prompted the identification of other capsid proteins amendable for ligand incorporation. These approaches have the potential to incorporate an increased number of complex ligands per virion. To date, the capsid proteins hexon, 10, 11 penton base, 12 minor capsid protein IX (pIX) [13] [14] [15] [16] [17] [18] and protein pIIIa 19 have been explored as platforms for the incorporation of heterologous peptides (reviewed by Vellinga et al. 20 ). We have been exploiting the adenovirus minor capsid pIX as an anchor to genetically incorporate large proteins. 17, 18 Protein IX is a small (14.3 kDa) protein of unknown structure that acts as capsid cement, stabilizing the interactions between hexon trimers on each facet of the virion. 21 Twelve molecules of pIX are associated with each facet of the icosahedron, with an overall stoichiometry of 240 pIX monomers per virion. 22 Although the main mass of pIX is thought to be located in the cavities between the so-called group-of-nine hexon capsomers, the postulated position of pIX in the capsid is being challenged. [23] [24] [25] [26] Nevertheless, we have recently demonstrated efficient and functional incorporation of the hyperstable singlechain antibody fragment 13R4 that was fused with pIX via a 75-Angstrom spacer. 18 The 13R4 was functional in the capsid as was evidenced by its capacity to bind Escherichia coli b-galactosidase.
Here we report the production of an adenoviral vector which is targeted to tumor cells presenting peptides of the CT antigen MAGE-A1 on HLA class I molecules of haplotype HLA-A1, via a scTCR (TCR A1M1 ) fused with adenovirus minor capsid pIX. To ensure enhanced protrusion of the scTCR at the virus surface, a 75-Angstrom a-helical spacer was included between pIX and the TCR. 17 We produced virus particles that were efficiently loaded with the pIX_TCR A1M1 fusion protein. The transduction efficiency of the HLA-A1/ MAGE-A1-positive melanoma cell lines MZ2-MEL3.0 and MZ2-MEL43 was strongly increased upon incorporation of the fusion protein. These findings represent (1) the first demonstration of a pIXscTCR-mediated adenovirus targeting of a cell type that is normally refractory to HAdV-5, and (2) further proof-of-principle of targeting the highly tumor-specific CT antigen/HLA class I complexes at the surface of human tumor cell lines.
Results

Establishment and characterization of the pIX_TCR
A1M1 -producing helper cell line
To establish a helper cell line stably expressing the pIX_TCR A1M1 fusion protein, 911 cells were transduced with the recombinant lentivirus LV.pIX_TCR A1M1 . A schematic overview of the pro-lentiviral DNA construct and the sequence eventually incorporated in the 911 genome is provided in Figure 1 .
After growing the cells for several weeks in selection medium (containing 200 mg ml À1 G418), western analysis on cell lysate was performed. This revealed pIX_TCR A1M1 protein amounts that were similar to the pIX level in 911 cells infected with HAdV-5.LUC virus (Figure 2a) . The protein size of pIX_TCR A1M1 was as expected (65.8 kDa). The percentage of pIX_TCR A1M1 -positive cells was determined by immunohistochemistry analysis (Figure 2b ). This showed more than 90% of the cells to be positive for pIX_TCR A1M1 . The pIX fusion protein appeared to be located mainly in the cytoplasm. Surprisingly, visualizing pIX_TCR A1M1 protein in the cells by using a conformation-dependent antibody recognizing the variable domain of the scTCR (Va12.1) was dependent on adenovirus infection of the cells (Figure 2c ). At 24 h postinfection, a Va12.1-mediated signal could be observed (cells were infected with the viral vector HAdV-5.CMVLUCDE1DE3DpIX, see next paragraph). Detection of pIX_scTCR A1M1 by Va12.1 antibody was absent at earlier time points of infection and in pIX_TCR A1M1 -negative 911 cells (result not shown). Confocal laser scanning microscopy was used to analyze the subcellular localization of the pIX_scTCR A1M1 protein after virus infection (Figure 2c ). Although the majority of the pIX_TCR A1M1 protein was observed in the cytoplasm, significant amounts were present in the nuclei of infected cells. In490% of the infected cells the pIX_TCR A1M1 fusion protein was readily detectable in the nucleus.
Efficient incorporation of pIX_TCR A1M1 in the virus capsid
Next, we tested the incorporation of pIX_TCR A1M1 into the capsid of the vector HAdV-5.CMVLUCDE1DE3DpIX. This vector lacks a functional pIX gene and carries the firefly luciferase reporter gene under control of the cytomegalovirus (CMV) promoter. After transduction of the 911/pIX_TCR A1M1 cells with the DpIX virus, the offspring virus particles were harvested and purified via the conventional cesium chloride (CsCl) purification method. This resulted in the virus HAdV-5/ pIX_TCR A1M1 . During purification, particle-associated pIX molecules were separated from the nonassociated Adenovirus targeting to cancer-testis antigens J de Vrij et al pIX molecules, as nonassociated variants do not copurify with the virus particles in the CsCl gradient. 17, 33 A schematic representation of the pIX_TCR A1M1 fusion protein, with its exposed single-chain TCR A1M1 positioned above the hexon capsomers, is depicted in Figure 3a .
The presence of pIX_TCR A1M1 in the virus particles was detected by western assay (Figure 3b ). The amount of pIX_TCR A1M1 in the HAdV-5/pIX_TCR A1M1 particles is slightly lower than the amounts of pIX in wild-type (wt) HAdV-5 particles. Loading was similar to the loading of pIX_13R4 in the previously produced virus HAdV-5/pIX_13R4. 18 The 13R4 is a single-chain antibody fragment directed against b-galactosidase, which is approximately 14 kDa smaller than the scTCR A1M1 . Incorporation of pIX_TCR A1M1 in the virus capsid was also shown by spot-blot analyses (Figure 3c ). Virus particles were spotted on a nitrocellulose membrane, followed by incubation with various antibodies. Upon spotting, the virus particles remain intact, indicated by the inability to detect the adenovirus core protein VII (pVII). Only after denaturation of the virus particles the pVII could be detected. From the appearance of the a-flag signal it can be concluded that flag epitopes of the pIX_TCR A1M1 fusion protein were accessible to immunoglobulins in the context of intact virus particles. For the a-flag and the a-pIX detection longer exposure times were used, resulting in increased background signals.
To further investigate the accessibility of the singlechain TCR A1M1 at the surface of the virus particles we performed an immunoprecipitation assay, in which the ability of the pIX_TCR A1M1 virus to bind to anti-TCR antibody-coated beads was analyzed (Figure 3d ). The pIX_TCR A1M1 virus was mixed with a control virus and subsequently incubated with Va12.1 or Vb1 antibody precoated beads. Both antibodies specifically recognize the variable (V) domain of the TCR A1M1 . After incubation, supernatant fraction, containing virus particles that were not bound to the beads, was applied to MEL2a cells, and the infection ratio of pIX_TCR A1M1 virus (containing the luciferase transgene) to control virus (containing the b-galactosidase transgene) was determined. As a result, significantly lower ratio for the Va12.1-or Vb1-treated samples was observed when compared to the ratio obtained from the samples without antibody treatment. This shows the binding of intact pIX_TCR A1M1 virus particles to the Va12.1 and Vb1 antibodies. Thus, it can be concluded that the V domains of the TCR A1M1 at the surface of the virus particles are accessible, suggesting that the scTCR may be free to interact with the HLA-A1/MAGE-A1 complex at the cell surface. . The vector used in this study is a third-generation, self-inactivating (SIN) vector, with major part of the 3 0 U3 region deleted, including the TATA box. 27 The Rev-responsive element (RRE), 28 the central polypurine tract (cPPT) [29] [30] [31] and the human hepatitis B virus-derived posttranscriptional regulatory element (PRE) are indicated. The encephalomyocardin virus internal ribosomal entry site (IRES) was obtained from pTM3. 32 The NPTII coding region (Neo Targeting of To compare incorporation efficiencies, virus lysates of HAdV-5 and HAdV-5/pIX_13R4 were included. The a-hexon antibody was included as a virus particle loading control. The predicted size of 14.3 kDa for wild-type pIX and 65.8 kDa for pIX_scTCR A1M1 was confirmed by the SDS-polyacrylamide gel electrophoresis (PAGE), as indicated in the figure. (c) Spot-blot analysis to detect the presence of pIX_TCR A1M1 in intact virus particles. Virus was spotted onto a membrane followed by incubation with multiple antibodies. As a control to show integrity of the particles upon the spot-blot treatments incubation with a-pVII was included, directed against the core protein VII. Only after denaturation pVII could be detected. To further analyze the specificity of targeting, MZ2-MEL2.2 cells (CAR neg , HLA-A1 pos , MAGE-A1 neg ) were loaded either with a control peptide (an irrelevant peptide derived from influenza virus A nucleoprotein), a MAGE-A1 peptide or were mock treated, and were subsequently exposed to the pIXscTCR virus (Figure 6c) . Incubation of the cells with MAGE-A1 peptide, but not with the control peptide, resulted in a significant increase in transduction by HAdV-5/pIX_TCR A1M1 . This effect did not occur in HAdV-5 transduction, confirming the dependency of HAdV-5/pIX_TCR A1M1 transduction on the presentation of the MAGE-A1 on HLA-A1. Compared to the MZ2-MEL3.0 cell line, the targeting efficiency to MAGE-A1-loaded MZ2-MEL2.2 cells was rather low. This can be explained by the significantly lower number of HLA-A1 molecules at the cell surface ( Figure 6d ).
Discussion
We demonstrate successful targeting of HAdV-5 vectors to HLA-A1/MAGE-A1-presenting tumor cells using an scTCR incorporated in the capsid as a genetic fusion with pIX. The pIX_TCR A1M1 -loaded virions transduced HLA-A1/MAGE-A1-expressing cells and HLA-A1-expressing cells loaded with MAGE-A1 peptides. These findings warrant further exploration of minor capsid pIX as an anchor for the insertion of targeting moieties.
The fusion of targeting proteins to pIX has some potential advantages. The use of pIX allows the incorporation of larger numbers of targeting molecules since it is present in 240 copies whereas 36 fiber molecules are present per virion. Furthermore, incorporation of large targeting ligands in the fiber, such as scTCRs or scFv's, may lead to a reduced number of fiber molecules per virion. 35 Intriguingly, pIX fusion proteins with sizes of up to 120 kDa can be accommodated in the capsid, although incorporation efficiency of the modified pIX (linked to an HSV1-TK/luciferase fusion protein) was slightly decreased. 36 However, this may be improved by the use of a-helical spacers. 17 To produce our targeting virus, with pIX_TCR A1M1 incorporated in the capsid, we used pIX-producing helper cell lines generated via lentiviral transduction. 37 By using this strategy of incorporation of pIX in a DpIX virus, the time-consuming process of making viruses with pIX modifications in the genome can be avoided. Efficient incorporation of modified pIX, for example, linked to single-chain antibody fragments, can be obtained. Adenovirus targeting to cancer-testis antigens J de Vrij et al location of the wt pIX, which is mainly nuclear. 38 As can be concluded from our results, the aberrant subcellular localization of pIX_TCR A1M1 does not hamper incorporation in the virus capsid. Since adenovirus particles are assembled in the nucleus, these results imply that a sufficient amount of pIX_TCR A1M1 was present in the nuclei during formation of the HAdV-5/pIX_TCR A1M1 virus. Indeed, we could confirm by confocal microscopy that during the adenovirus infection significant amounts of pIX_TCR A1M1 are localized in the nucleus. The targeting specificity to tumor cells expressing the MAGE-A1-derived epitope in the context of HLA-A1 was demonstrated via different approaches. First, transduction of the HLA-A1/MAGE-A1-positive MZ2-MEL3.0 cells was increased up to 10-fold by the incorporation of pIX_TCR A1M1 in the virus capsid. The targeting efficiency in another HLA-A1/MAGE-A1-positive cell line, MZ2-MEL43, appeared to be higher. Specificity was also evident from experiments in which HLA-A1-positive/MAGE-A1-negative MZ2-MEL2.2 cells were loaded with MAGE-A1 peptides. This resulted in a significant increase in transduction efficiency. The targeting specificity was lower than achieved on MZ2-MEL3.0 cells. This may be due to distinct presentation of synthetic peptides when compared to endogenously processed and presented peptides at the cell surface. Also, MZ2-MEL2.2 cells express fewer HLA-A1 molecules at their cell surface than MZ2-MEL3.0 cells (Figure 6d) . Furthermore, the targeting efficiency to MZ2-MEL3.0 could be reduced by blocking HLA, either via incubation of the cells with a-HLA-ABC antibody, or alternatively, via the expression of the HCMV US11 gene. The US11 causes degradation of newly synthesized MHC class I heavy chains by mediating their dislocation from the ER into the cytosol. 34 For the antibody incubation, as well as the US11-mediated downregulation, the blocking of targeting was not 100%. Apparently, the incubation of cells with a-HLA-ABC antibody was not sufficient to block all HLA-A1 molecules. In case of the US11-mediated downmodulation, flow cytometry analysis showed that a small but detectable fraction of the cell population had not been transduced (GFP negative), and thus did not downregulate HLA class I presentation, which probably explains the incomplete block of targeting.
We report successful targeting of HAdV-5 via fusion of a specific targeting moiety to capsid pIX. It has been speculated that targeting via pIX results in entrapment of Adenovirus targeting to cancer-testis antigens J de Vrij et al the virions in the endosomes, caused by high-affinity interaction between the pIX fusion protein and the cellular receptor. 16 However, binding of T-cell receptors to their target MHCI/peptide complex is known to have low affinity. 39 This may allow the scTCR-containing virions to escape from the endosome. Alternatively, binding of the virus particles to the HLA-A1/MAGE-A1 complex may have resulted in a distinct internalization, that is, differing from the normal HAdV-5 internalization via clathrin-coated vesicles. Cellular internalization mediated by binding to MHCI molecules is exploited by Simian virus 40, which enters the cell via a unique pathway that involves caveolae, rather than clathrin-coated pits. 40 Interestingly, HLA class I has been suggested as an alternative receptor for HAdV-5. 41 The fact that the scTCR used in this study is biologically active at the surface of the adenovirus supports the feasibility of targeting adenovirus vectors by fusing complex polypeptide molecules, such as scTCRs or scFv fragments, to capsid pIX. Normally, such complex polypeptides are routed via the protein secretory pathway. This aspect might hamper functional incorporation in the capsid of adenovirus particles, which are assembled in the nucleus. The reducing environment in the cell prevents the formation of disulfide bridges, which may result in improper folding of these proteins. 42 Another obstacle for the implementation of scTCRs in adenoviral vectors might be that the relatively large scTCRs hamper correct virion formation or might interfere with crucial processes necessary for virus propagation. Initial attempts to produce adenovirus vectors with an scTCR fragment genetically fused to a knobless fiber protein were unsuccessful. 43 Incorrect folding and/or trimer formation of the fiber protein due to the presence of the scTCR fragment was reported to be the most likely explanation. The incorrect fiber formation might have caused the inability to rescue the virus, even though the mutated viral DNA was introduced into the target cell line. However, more recently the successful development of an scTCR-containing adenovirus has been reported. 6 Our results, with an scTCR bound to the minor capsid pIX, emphasize the potential of scTCRs for obtaining transductional specificity in adenoviral vectors. The pIX_TCR A1M1 fusion protein was Adenovirus targeting to cancer-testis antigens J de Vrij et al incorporated in the capsid with high efficiency. Although it remains to be established whether all scTCRs are functional if fused with pIX, our results clearly demonstrate the functionality of at least part of the scTCRs. The variable domains of the scTCR, which mediate binding to the HLA-A1/MAGE-A1 target complex, were accessible to antibodies in the context of intact virions, which was shown via immunoprecipitation of the virus on Va12.1-or Vb1-coated beads, and alternatively, via downregulation of transduction as a result of Va12.1 incubation. The presence of the 75-Angstrom a-helical spacer 17 in between the scTCR and pIX domains might have been crucial to generate sufficient flexibility for proper orientation of the scTCR at the capsid surface. Detailed studies on elucidating the process of scTCR folding during virus infection would be of great interest. Our immunohistochemistry analysis on the 911/pIX_T-CR A1M1 cell line yielded staining with the conformationdependent antibody Va12.1, only after adenovirus infection. It is tempting to speculate that the scTCR only adopts its proper conformation upon change of the intracellular milieu upon induction of adenovirusinduced cell death.
The pIXscTCR-containing virus used in this study was not de-targeted, as the CAR-binding elements, the heparan sulfate proteoglycans-binding elements and the plasma protein-binding elements are still present in the capsid. For the final aim of in vivo tumor therapy via delivery of an HAdV-5 vector, these elements should be abolished. Also, it would be interesting to test whether shortening of the fiber shaft or complete removal of the fiber improves targeting efficiency, for instance by reducing steric hindrance of the pIXscTCR molecules by the protruding fiber proteins. Currently, pIXscTCR targeting in the context of fiber mutations is under investigation.
Our approach as described here utilizes the targeting of CT antigen epitopes that are presented at the cell surface of tumor cells by HLA class I molecules. This principle differs from previously reported retargeting approaches of adenovirus-based vectors, which encompass the targeting of 'overexpression' receptors like Her2/neu 44 or the epidermal growth factor receptor. 45 The expression profile of the CT antigens is generally much more specific compared to the expression profile of the 'more conventional' target molecules such as the overexpressed receptors. The fact that HLA class I/CT antigen complexes can elicit a highly specific response of the immune system has prompted many studies on immune cell modifications with the aim to direct the modified cells toward tumor cells. 4 However, tumor therapies via such approaches may not be feasible since the process of isolating, modifying and expansion of patient immune cells is likely to be difficult and time consuming. Viral vector-based cancer gene therapy might be a more suitable strategy. Genetic modification of adenoviral vectors, which are the most widely used virus vectors in clinical tumor gene therapy studies, is relatively easy. Besides, adenoviruses have a good safety profile and can be produced with high titers.
Our results show that HAdV-5 vectors can be genetically modified to mediate greatly enhanced gene delivery into tumor cells by targeting HLA class I/CT antigen complexes. The successful combination of two aspects with great potential in cancer gene therapy, adenovirus as a vector and CT antigens as a target, clearly warrants further exploration. Follow-up studies are under way, and especially the fusion of other scTCRs to pIX (directed against other HLA class I/CT antigen complexes), and the evaluation of in vivo performance of the modified HAdV-5 vectors will be of great interest.
Materials and methods
DNA constructs
The lentiviral vectors used in this study were described in earlier studies. 37 Plasmid pLV.CMV.pIXflag75AscT-CR A1M1 .bc.neo, abbreviated as pLV.pIX_TCR A1M1 , was constructed by standard cloning procedures. The pLV plasmid contained a G418 resistance gene (neo) downstream of the pIX_TCR A1M1 sequence, separated by an internal ribosome entry site (bc). In between the pIX and scTCR sequence, sequences are present that encode a flag tag and a 75-Angstrom spacer. Insertion of this spacer has been shown to greatly enhance presentation of pIX-fused proteins at the virus capsid. 17 The gene for pIXflag75 was obtained from the pcDNA3.1-based construct pAd5pIXflag75MYC. 17 The gene encoding scTCR A1M1 was subcloned from the retroviral vector pBullet.VaVbCb. 46 The scTCR A1M1 sequence of pBullet. VaVbCb was originally constructed from the Va, Vb and Cb sequences from an HLA-A1/MAGE-A1-specific CTL clone MZ2-82/30 of patient MZ2. . 6 The status of the previously uncharacterized cell line MZ2-MEL43 is CAR neg /HLA-A1 pos /MAGE-A1 pos , as determined by flow cytometry analysis and shown in Figure  6a in this paper. The HAdV-5 E1-transformed cell line 911 was used to propagate and titer adenovirus vectors. 48 
Lentiviral and retroviral transductions
The recombinant lentivirus LV.pIX_TCR A1M1 was produced as described elsewhere. 37 The lentivirus titer was determined by p24 enzyme-linked immunosorbent assay, assuming that 1 ng p24 equals 2.5 Â 10 3 transducing units. 49 To establish a helper cell line stably expressing pIX_TCR A1M1 , 911 cells were transduced with the recombinant lentivirus, resulting in the cell line 911/ pIX_TCR A1M1 . Infection was done with five transducing units per cell. To select for stably transduced cells, the cell line 911/pIX_TCR A1M1 was cultured in medium supplemented with 200 mg l À1 G418 (Invitrogen, Breda, the Netherlands).
The retroviral vector pLZRS-US11-IRES-EGFP was made by subcloning the HCMV US11 cDNA fragment into the pLZRS-IRES-EGFP vector. 50 This construct was ), which was removed 24 h before collecting the virus. MZ2-MEL3.0 cells, grown on retronectin-coated dishes (Takara, Japan), were transduced with the recombinant viruses to create cells stably expressing US11 and the control construct.
Adenovirus vectors
The 911/pIX_TCR A1M1 helper cell line was transduced with the replication-deficient adenoviral vector HAdV-5.CMVLUCDE1DE3DpIX. Production and characteristics of this vector are described elsewhere. 17 The vector carries a firefly luciferase transgene under control of the human CMV immediate-early promoter. In this vector the pIX gene had been deleted from the genome. Three days after transduction, the offspring virus was harvested and purified by CsCl banding, resulting in the virus HAdV-5.CMVLUCDE1DE3DpIX+pIX_TCR A1M1 (indicated in this paper as HAdV-5/pIX_TCR A1M1 ). Adenovirus particle titers were determined by measuring optical density at 260 nm, using a standard protocol. 51 The control virus used in all retargeting experiments was HAdV-5.CMVLUCDE1DE3 (indicated as HAdV-5).
Immunohistochemistry
Immunohistochemistry was performed on the helper cell line 911/pIX_TCR A1M1 , with or without HAdV-5.CMVLUCDE1DE3DpIX infection. Infection was performed with 1000 virus particles per cell, 24 h before fixation. After washing with phosphate-buffered saline (PBS), the cells were fixed in acetone/methanol (1:1) for 10 min at room temperature. Staining was performed with the antibodies a-pIX (rabbit polyclonal (1:500), kindly provided by Dr Keith Leppard, University of Warwick, UK), 52 Va12.1 (Pierce-Endogen Biotechnology, Rockford, IL, USA) and a-hexon (clone BOD604, fluorescein isothiocyanate (FITC)-conjugated, Biodesign International, Saco, ME, USA). FITC-labeled antibodies (Jackson ImmunoResearch, France) were used as secondary antibody. Upon analysis of the uninfected cells, the nuclei were stained using propidium iodide. Exact detection procedure has been described previously. 18 Wide-field microscopy was performed with a Leica DM-IRBE microscope. Confocal laser scanning microscopy was performed on a confocal microscope system (model TCS/SP2; Leica). Z-series images (slice spacing 0.45 mm) were acquired with a 63_ NA 1.4 plan Apo objective and were analyzed with Leica confocal software.
Immunoblotting procedures
Western analysis was performed to analyze production of pIX_TCR A1M1 in the helper cells and to analyze incorporation efficiency of pIX_TCR A1M1 in the virus capsid. Cell lysates were made in radioimmunoprecipitation assay lysis buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% SDS, 0.5% DOC, 1% NP40). Protein concentrations were measured with the bicinchoninic acid protein assay (Pierce Biotechnology, Perbio Science BV, Etten-Leur, the Netherlands). Virus lysates were prepared by adding 5 Â 10 9 virus particles directly to western sample buffer. The pIX variants were visualized with rabbit polyclonal a-pIX serum (1:2000) . 52 Goat polyclonal a-hexon (1:1000) (Abcam, Cambridge, UK) was used as a virus particle loading control. Secondary antibodies were horseradish peroxidase (HRP)-conjugated goat-a-rabbit and rabbit-a-mouse (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The western blotting and detection procedures have been previously described. 17, 37 A spot-blot type analysis was used to detect viral capsid proteins in intact virus particles. Immobilon membrane (Millipore, Etten-Leur, The Netherlands) was activated with methanol, washed for 10 min with PBS and virus (3 Â 10 9 particles) was spotted onto the membrane. Virus was spotted as intact particles (untreated) or as virus lysate (denatured through adding western sample buffer plus 5 min incubation at 98 1C). This was followed up by blocking for 1 h in Soja milk (Alpro soja, Breda, The Netherlands), and washing twice for 10 min with 0.2% Tween 20 in PBS. Thereafter, probing of capsid proteins was performed according to the same protocol as applied for the western analysis. The primary antibodies used were mouse monoclonal afiber knob (1D6.14, 1:1000), 53 goat polyclonal a-hexon (1:2000; Abcam), a-flag (1:500) (a-flag M2 Affinity Gel Freezer-Safe; Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands), rabbit polyclonal a-pIX (1:2000) 52 and a-pVII antibody (1:500) (kindly provided by Saw See Hong, Laboratoire de Virologie et Pathogénèse Virale, Lyon, France). Secondary antibodies used were HRPconjugated goat-a-rabbit and rabbit-a-mouse (Santa Cruz Biotechnology).
Binding of virus particles to anti-TCR-coated beads
The ability of the pIX_TCR A1M1 virus to bind to anti-TCRcoated beads was investigated through an immunoprecipitation assay. Protein G Sepharose beads (30 ml; Pierce Biotechnology) were incubated with 1 mg of antibody (Va12.1 or Vb1), for 2 h at 4 1C in 600 ml cold PBS. Antibody-coupled beads were added to 1 ml DMEM without serum, containing two types of virus; HAdV-5.CMVLUCDE1DE3DpIX (5 Â 10 10 particles), and HAdV-5.CMVLacZDE1 (5 Â 10 10 particles). Control samples were incubated with beads only. After incubation for 12 h at 4 1C, 50 ml of the supernatant was added to 450 ml DMEM (containing 8% FBS), which was subsequently applied on MEL2a cells in a 24-well plate. After 24 h, the expression levels of intracellular luciferase and b-galactosidase were determined. To this end, the cells were washed once with PBS, and lysed in 100 ml LUC-lysis mix (25 mM Tris-phosphate (pH 7.8), 2 mM CDTA, 2 mM DTT, 10% glycerol and 1% Triton-X in PBS). After shaking for 15 min at room temperature, lysates were centrifuged (10000 g, 10 min). Luciferase production was determined with Promega Luciferase Assay, and b-galactosidase production was determined with the Tropix Galacto-Light reporter gene assay (Applied Biosystems, Bedford, MA, USA). Light intensity measurement was performed in a Victor Wallac 2 microplate reader (PerkinElmer, Inc., Waltham, MA, USA).
Virus transduction assays
Transduction efficiencies with HAdV-5/pIX_TCR A1M1 and HAdV-5 were analyzed by measuring luciferase Adenovirus targeting to cancer-testis antigens J de Vrij et al production. For all virus transduction assays, transduction was performed in 24-well plate, with 1000 viral particles per cell, in 500 ml DMEM/8% FBS. After 24 h, luciferase production was measured as described above (25 ml luciferase assay reagent was added to 10 ml lysate).
Incubation of cells with a-HLA-ABC antibody (ascites) was performed to test downmodulation of targeting. The cells were incubated for 12 h with 20 mg ml À1 a-HLA-ABC (in medium), which was removed from the cells before adding the virus. TCR blocking analysis was performed by incubating the virus (10 8 particles) for 12 h (4 1C) with 150 ng Va12.1 antibody in 100 ml PBS supplemented with 2% horse serum. After adding 400 ml medium, the virus was added to 10 5 cells (resulting in a titer of 1000 particles per cell).
For peptide loading of the MZ2-MEL2.2 cells, 500 ng MAGE-A1 peptide, or 500 ng of an irrelevant peptide derived from influenza virus A nucleoprotein antigen 54 was added per well 2 h prior to adding the virus.
Flow cytometry
To perform flow cytometry analysis on the different cell lines, the cells were trypsinized, resuspended in PBS (containing 0.5% bovine serum albumin and 0.02% sodium azide), and were incubated with antibodies. The cells were incubated with saturating conditions of a-CAR antibody, 
